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Abstract
Zika virus (ZIKV) was initially thought to cause only mild, self-limiting
symptoms. However, recent outbreaks have been associated with the
autoimmune disease Guillain-Barré syndrome and causally linked to a
congenital malformation known as microcephaly. This has led to an urgent
need for a safe and effective vaccine. A comprehensive understanding of the
immunology of ZIKV infection is required to aid in the design of such a vaccine.
Whilst details of both innate and adaptive immune responses to ZIKV are
emerging, further research is needed. As immunopathogenesis has been
implicated in poor outcomes following infection with the related dengue virus,
identification of cross-reactive immune responses between flaviviruses and the
impact they may have on disease progression is also of high importance.
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Introduction
Zika virus (ZIKV) was first isolated from a febrile non-human 
primate in the Zika Forest of Uganda in 19471 (Figure 1). Very 
few cases of human infection were reported in the subsequent 
decades2 until 2007, when an outbreak occurred on the island 
of Yap in the Federated States of Micronesia3. In 2013, some 
30,000 cases of ZIKV infection were recorded in French 
Polynesia4. Up to this point, the virus was believed to cause only 
a mild, self-limiting febrile illness. However, ZIKV transmission 
in French Polynesia was associated with the development of 
the neurological autoimmune disease Guillain-Barré syndrome 
(GBS)5.
After 2013, ZIKV emerged in South America, first appearing 
in Chile6 and then going on to cause a large-scale outbreak in 
Brazil. It is estimated that by the end of 2015 between 440,000 
and 1.3 million people had been infected in Brazil7. This increase 
in ZIKV prevalence was coincident with a rise in the occurrence 
of a congenital malformation known as microcephaly8. This 
birth defect results in a reduction in head size, causing several 
complications, including developmental delay.
Owing to the severe nature of complications arising from ZIKV 
transmission, the development of a safe and effective vaccine 
has become a priority for the research community. An extensive 
understanding of the immunology of ZIKV infection is 
vital to inform the design of such a vaccine. Owing to the 
relatedness of ZIKV to other flaviviruses that co-circulate in 
endemic regions, it is also of importance to understand how 
cross-reactive immune responses might impact on the outcome of 
ZIKV infection.
Zika virus
ZIKV is a member of the flavivirus family, which includes other 
important human pathogens such as dengue virus (DENV), 
yellow fever virus (YFV), West Nile virus (WNV), Japanese 
encephalitis virus, and tick-borne encephalitis virus. ZIKV is an 
arthropod-borne virus that is transmitted via the bite of infected 
aedes mosquitoes9. Seemingly unique amongst flaviviruses, 
ZIKV can also be transmitted by the aforementioned perinatal 
route as well as via sexual contact10,11. Furthermore, the sexual 
transmission of ZIKV can potentially occur long after acute 
infection, as virus has been detected in semen more than 6 months 
after symptomatic disease12. ZIKV has also been shown to cause 
damage to the testes and affect fertility in a mouse model of 
infection13.
As with other flaviviruses, ZIKV has a single-stranded 
positive-sense RNA genome that is translated into a single 
polyprotein. This polyprotein is cleaved into three structural 
proteins—capsid, pre-membrane (PrM), and envelope (E)—and 
seven non-structural (NS) proteins: NS1, NS2a, NS2b, NS3, NS4a, 
NS4b, and NS5. The surface structure of the mature ZIKV virion 
is composed of 90 anti-parallel E dimers arranged in a herringbone 
formation14. This is similar to the structure of both DENV and 
WNV.
Immune responses to Zika virus
The innate immune response
The interferon (IFN) response plays a critical role in the control 
of flaviviruses, as shown by the increased susceptibility of mice 
lacking components of the IFN pathway to flaviviral infection15,16 
and the numerous mechanisms employed by flaviviruses to 
counteract this control17,18.
Several in vitro studies using both primary human cells and 
human-derived cell lines have been undertaken to assess the IFN 
response to ZIKV infection. Dependent on the cell type used, 
ZIKV infection resulted in the production of type I (α, β), type 
II (γ), and type III (λ) IFN as well as the activation of several 
IFN-stimulated genes (ISGs)19–22.
Investigations to determine the mechanisms employed by ZIKV to 
dampen the IFN response have also been carried out. The ZIKV 
NS5 protein has been shown to degrade STAT2, a signalling 
molecule involved in the type I IFN pathway23. This limits type I 
IFN signalling and allows increased viral replication. This 
appears to be a species-specific interaction, as ZIKV NS5 is 
Figure 1. Timeline of the spread of Zika virus (ZIKV). Following its isolation in Uganda in 1947, ZIKV caused only sporadic incidences of 
human infection until an outbreak on the island of Yap in 2007. Since then, the virus has spread through the South Pacific to South America, 
resulting in large-scale transmission that is associated with severe complications such as Guillain-Barré syndrome and microcephaly.
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unable to degrade murine STAT2, contributing to the inefficient 
replication of ZIKV seen in immunocompetent mice and the 
increased susceptibility of mice lacking components of the type I 
IFN signalling pathway to infection with ZIKV.
However, it should be noted that this study relies on the over-
expression of NS5. Furthermore, another investigation using 
infected human dendritic cells suggests another mechanism 
of ZIKV-mediated IFN inhibition. That study found ZIKV 
infection to result in the antagonism of STAT1 and STAT2 
phosphorylation24. As yet, it is unclear which mechanism might 
occur first or whether both take place during natural infection.
The antibody response
The structural proteins E and PrM along with the secreted 
protein NS1 represent the major targets for flavivirus-specific 
antibodies25,26. Initial studies show that the ZIKV-specific antibody 
response conforms to this pattern27, although additional compre-
hensive mapping experiments would be beneficial.
Studies have shown ZIKV-specific antibodies to be crucial for 
viral control in mouse models of infection. A DNA vaccine 
comprising ZIKV PrM and E protected mice from viral challenge, 
resulting in an absence of detectable viremia. This protection was 
mediated by E-specific antibodies, as demonstrated by passive 
transfer experiments28. This same vaccine was also found to be 
protective in rhesus macaques29.
Several human monoclonal antibodies capable of neutralising 
ZIKV both in vitro and in vivo have been isolated. These include 
antibodies to the quaternary E dimer epitope, which cross-
react between ZIKV and DENV30–32. Antibodies recognising 
domain III of ZIKV E protein, which reduce disease symptoms 
and mortality in ZIKV-infected mice, have also been identified33. 
In addition, two antibodies, which recognise epitopes spanning 
multiple domains of the ZIKV E protein, were found to protect 
mice in a post-exposure model34.
The T-cell response
The immunodominant DENV-specific CD8+ T-cell response is 
directed toward the NS proteins NS3 and NS5, although epitopes 
have been identified across the genome. Further work is required 
to determine which ZIKV proteins are the major targets of the 
T-cell response in humans.
One study in IFN receptor (IFNR) type I-deficient mice found 
ZIKV-specific CD8+ T cells to predominantly target the PrM, 
E, and NS5 proteins. It was demonstrated that such cells have a 
protective role during infection, as adoptive transfer led to a 
reduction in virus load following challenge35. In an IFNR type I-
deficient HLA transgenic mouse model, ZIKV-specific T cells 
were found to recognise epitopes across all 10 proteins. These 
T cells were also shown to be protective during ZIKV infection, 
as immunisation with peptide epitopes resulted in a reduction in 
virus load following challenge36. This reduction was abrogated 
following the depletion of CD8+ T cells.
Depletion of T cells resulted in ZIKV-induced weight loss in 
both wild-type and IFN-deficient mice. This study also found 
CD4+ and CD8+ T-cell responses toward ZIKV to be dampened 
during pregnancy37. If this is the case for human ZIKV infections, 
it could have implications for the development of microcephaly.
Caution is required when extrapolating data from mouse studies 
to be applied to humans. With the exception of the HLA trans-
genic model, the mice used in the experiments described above 
display distinct major histocompatibility complex molecules 
to humans. This will lead to the recognition of different T-cell 
epitopes. In addition, many of these studies were carried out in 
mice lacking components of the IFN pathway, which plays an 
important role in the generation of a fully functional T-cell 
response.
Studies investigating T-cell responses during human ZIKV 
infection are sparse at present. CD4+ T cells that proliferate in 
response to stimulation with E and NS1 have been identified in 
humans who had experienced a recent ZIKV infection27, and 
in silico analysis has been used to predict ZIKV T-cell epitopes38. 
Therefore, substantial further research is required to confirm a 
protective role for T cells during ZIKV infection in humans.
Flavivirus cross-reactive immune responses: 
immunopathogenesis or protection?
ZIKV transmission is taking place in areas where other flavivi-
ruses are circulating. Therefore, ZIKV infections will be occur-
ring in populations with previous flavivirus immunity. It will be of 
importance to understand how such immunity will impact on 
the outcome of ZIKV infection. Particular focus has been given 
to cross-reactivity between DENV and ZIKV, as the E proteins 
are closely related30. Moreover, immunopathogenesis has been 
implicated in contributing to the severe symptoms of DENV 
infection.
DENV co-circulates as four closely related serotypes, and 
sequential infections are common. Individuals experiencing a 
secondary or subsequent infection are more likely to develop 
serious complications39,40, suggesting a role for virus-specific 
immunity in pathogenesis. The mechanism for antibody involve-
ment is well defined. Subneutralising levels of DENV-specific 
antibodies can lead to opsonisation of virus particles and 
increased entry into Fc receptor-bearing cells41. Such cells are a 
major site of DENV replication, thus leading to increased viral 
replication in a phenomenon known as antibody-dependent 
enhancement (ADE).
The role of serotype cross-reactive T cells in DENV patho-
genesis is more contentious. CD8+ T cells that preferentially 
recognise epitopes derived from the primary infecting serotype 
have been identified42. The expansion of cells generated during a 
primary infection but displaying a low avidity for the current 
infecting serotype may result in delayed viral clearance and higher 
viral loads. However, studies in both humans and mice have 
suggested a protective role for serotype cross-reactive T cells43–46.
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The role that immunopathogenesis plays in the outcome of 
DENV infection along with the genetic similarities and co-circula-
tion of both ZIKV and DENV lead to some important questions 
that need addressing. Can DENV-specific immune responses 
affect the outcome of ZIKV infection and vice versa? How 
might pre-existing flaviviral immunity impact on the maternal– 
fetal transmission of ZIKV? What implications might the answers 
to these questions have for vaccine design?
Dengue virus cross-reactive antibodies
Several studies have identified antibodies that are 
cross-reactive between DENV and ZIKV27,30–33,47,48. Furthermore, 
it has been demonstrated that DENV-specific antibodies are able 
to enhance infection of Fc receptor-bearing cells with ZIKV 
in vitro31,47,49,50. Adoptive transfer of DENV convalescent plasma 
enhanced pathogenesis in a mouse model of ZIKV infection49, 
suggesting a role for ADE in vivo. Conversely, pre-existing 
DENV immunity did not result in more severe ZIKV disease in 
rhesus macaques51.
However, both of these studies have limitations that should be 
considered when interpreting their data. The adoptive transfer 
experiments used immunocompromised mice, and the macaques 
displayed no symptoms of disease following infection. In 
addition, differences in experimental design may account for the 
disparate findings seen. Whilst antibodies alone were transferred 
into the mice two hours prior to infection, the macaques were 
infected with DENV two and a half years before ZIKV expo-
sure. This may impact on the nature of the DENV-specific anti-
body response present. Moreover, in the macaques, other com-
ponents of a DENV-specific immune response would be present 
alongside the antibodies, potentially affecting the outcome of ZIKV 
infection.
Therefore, whether or not the mechanism of ADE is at play 
during natural infection requires further research, and in par-
ticular the development of serological reagents to distinguish 
previous ZIKV and DENV infections is essential to probe 
epidemiological cohorts. DENV-specific antibodies with the ability 
to neutralise ZIKV infection in vitro have been identified27,30–32, and 
monoclonal antibodies isolated from patients with dengue have 
been found to protect mice during ZIKV challenge32,33.
Of importance to this mechanism is the question of which cell 
types provide the major site of replication for ZIKV. If ZIKV 
predominantly replicates in non-Fc receptor-bearing cells, then 
DENV-specific antibodies are unlikely to have a major impact 
on pathogenesis. There is mounting evidence to suggest that the 
tissue tropism of ZIKV is distinct from that of DENV52.
It may be that certain serotypes of DENV differ in their ability to 
generate a pathogenic or a beneficial antibody response. It may 
also be of importance how many previous DENV infections an 
individual has been exposed to. One previous DENV infection 
may enhance Zika disease, whereas two or more may turn out 
to be protective, as is the case for sequential DENV infections53. 
As is also the case for DENV, the time gap between infections 
could be crucial54.
Dengue virus cross-reactive T cells
In addition to antibodies, DENV and ZIKV cross-reactive 
T cells have been identified. The study described above involv-
ing humanised mice identified T cells specific for several 
epitopes that were either ZIKV specific or cross-reactive between 
ZIKV and DENV. Both types of peptide epitope were used to 
immunise mice prior to ZIKV challenge and were found to 
be protective36. Although the peptides used in this study were 
divided into two groups based on their cross-reactivity to DENV, 
all were exactly sequence-matched to the strain of ZIKV used 
to challenge the mice. To develop these findings further, it would 
be useful to ascertain whether T cells specific for DENV that 
are partially cross-reactive toward ZIKV are also protective.
In another mouse model of infection, CD8+ T cells from 
ZIKV-infected wild-type mice were found to protect type I IFNR 
knockout mice during both ZIKV and DENV infection55. It has 
also been shown that adoptive transfer of DENV-specific CD8+ 
T cells can confer protection during ZIKV infection of type I 
IFNR knockout mice56.
The previously mentioned study that found memory T cells 
specific for NS1 and E following ZIKV infection of humans 
demonstrated these cells to be poorly cross-reactive with DENV, 
even in those individuals who had experienced a previous DENV 
infection27. In contrast, in silico analysis has identified T-cell 
reactivity conserved across several flaviviruses, including ZIKV 
predominantly found in the NS3 and NS5 proteins38. In addition, 
a study of a human cohort revealed previous DENV exposure 
to affect the magnitude, timing, and quality of the ZIKV-specific 
T-cell response57. Substantial further research is required to 
establish the role that T cells play during ZIKV infections and 
whether or not DENV cross-reactive T cells can contribute to 
pathogenesis or protection.
Vaccine development
Several vaccine strategies have been found to be protective in 
either mouse or non-human primate models of ZIKV infec-
tion. These include DNA vaccines28,29,58,59, RNA vaccines60,61, live 
attenuated virus62, inactivated virus28,29,63, and virus-like particles64. 
Vaccines have also been found to block the transmission of ZIKV 
to the foetus of pregnant mice65. Some of these vaccines are 
currently in the early stages of clinical trials in humans (Table 1).
Most of these vaccines are aimed at generating antibodies 
specific for the ZIKV virion. Analysis of other flaviviral vaccines 
has shown levels of E-specific antibodies to correlate with 
protection in both animals and humans66. However, it has been 
suggested that the lack of efficacy of the recently licensed 
DENV vaccine may be due in part to its inability to generate an 
effective DENV-specific T-cell response, as the NS proteins 
contained within it are derived from YFV67. Therefore, develop-
ing a ZIKV vaccine that aims to induce both an antibody and a 
T-cell response may prove beneficial.
A ZIKV vaccine may need to be used in pregnant women or 
immunocompromised individuals, which could raise safety 
concerns with live attenuated vaccines because of the risk of 
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Table 1. Current Zika virus vaccine trials.
Phase Name Strain Target Strategy Sponsor References
I
VRC-ZKADNA085-00-VP H/PF/2013 PrM-E DNA vaccine National Institutes of Health 28,29
VRC-ZKADNA090-00-VP H/PF/2013 PrM-E DNA vaccine National Institutes of Health
GLS-5700 Consensus PrM-E DNA vaccine GeneOne 59
ZPIV PRVABC59 Whole virion
Inactivated 
virus
Walter Reed Army Institute of 
Research/National Institute of 
Allergy and Infectious Diseases
28,29
MV-ZIKA E Viral vector Themis
I/II mRNA-1325 Micronesia 2007 PrM-E mRNA vaccine Moderna Therapeutics 61
E, envelope; PrM, pre-membrane.
reversion. Such vaccines are, however, cost-effective to produce 
and often result in durable immunity, even after one dose. Other 
vaccine strategies present viable alternatives to live attenuated 
vaccines. DNA plasmid vaccines are easy to produce and are 
physically and genetically stable, and inactivated vaccines are 
already in use for other flaviviruses. However, both of these 
vaccine strategies may turn out to be less immunogenic as 
compared with a live vaccine66.
Another consideration during the development of a ZIKV vaccine 
is that it may be difficult to determine the threshold of protec-
tion to prevent foetal transmission and microcephaly. Complete 
sterilising immunity may be required to prevent infection of the 
foetus, and assessing whether this has been achieved during a 
vaccine trial in which the endpoint is prevention of symptomatic 
infection will be challenging.
Monitoring should be undertaken to ensure that vaccination does 
not lead to increased susceptibility to severe outcomes following 
infection with other flaviviruses such as DENV. The mechanism 
of GBS following ZIKV infection, which occurs in an estimated 
1 in every 4,000 cases5, is not yet clear. However, auto-reactive 
antibodies have been shown to be present during GBS triggered 
by other pathogens68. It will therefore be important to monitor 
vaccinees for symptoms of GBS.
Conclusions
Since the association between ZIKV and severe complications 
such as GBS and microcephaly emerged, much research has been 
carried out, resulting in a substantial increase in our knowledge 
of the immunology of ZIKV infection. Proteins and, in some 
instances, epitopes targeted by antibodies and T cells during human 
ZIKV infection have been determined. Following the develop-
ment of mouse models, protective antibody and T-cell responses 
have been identified. Several vaccine strategies have been tested 
in animal models, and early clinical trials have begun in humans. 
Caution and further insight are required in order to ensure that 
such vaccines will have no detrimental effects and will provide 
long-term protection.
Immunopathogenesis has been implicated as a contributing 
factor to DENV disease. Sequential infections with DENV and 
ZIKV are likely to occur because of the co-circulation of both 
viruses in endemic areas. DENV/ZIKV cross-reactive immune 
responses have already been identified, which is perhaps unsur-
prising given the sequence homology between the two viruses. 
A DENV vaccine is currently licensed for use in several 
countries experiencing ZIKV outbreaks. Gaining a comprehen-
sive understanding of the effect that DENV immunity has during 
ZIKV infection and vice versa is crucial for the design of safe 
vaccine strategies.
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